STOCKS TELEGRAPH

Tag: SVRA stock

  • Savara Inc. (SVRA) stock is experiencing a decrease of 5.13% – Learn why?

    Savara Inc. (SVRA) stock is experiencing a decrease of 5.13% – Learn why?

    Savara Inc. (SVRA) has seen a decrease of 5.13% in the current market. However, the last trading session closed at $1.17 with an increase of 3.54%.

    Third Quarter 2021 Financial Results by SVRA – More About it

    SVRA announced third quarter 2021 financial results on 12th November 2021. The company reported a net loss of $10.5 million with research and development costs of $6.5 million. The cost of screening patients and progressing the IMPALA-2 trial for the molgramostim development program increased by roughly $3.2 million. Moreover, general, and administrative expenses declined by 2 million and reached $3.4 million. Last but not the least, cash and cash equivalents came out to be $171 million.

    What’s new?

    The team is laser-focused on moving forward with the pivotal Phase 3 IMPALA 2 research, which is currently enrolling people. SVRA is also pleased with the progress made in the preceding quarter. Furthermore, an increasing number of locations are assessing and enrolling patients. Not only that, but the EMA accepted the proposed amended PIP, marking a significant regulatory milestone for the company.

    Moreover, despite the unknown impact of COVID-19 and the flu over the winter, the firm remains confident in its prediction of a 20-month recruitment timeline and top-line results by the end of Q2 2024. Finally, the corporation considerably increased inhalation delivery and biological product experience with the addition of Peter Clarke and Charles LaPree to the manufacturing, regulatory, and quality operations.

    Second Quarter 2021 financial Reports by SVRA – How was the quarter?

    SVRA reported second-quarter 2021 financial results on 12th August 2021. The company experienced a net loss of $10.9 million with research and development costs of $1.2 million. Moreover, the general and administrative expenses were recorded as $3.2 million with an incline of 1.2% million. Last but not the least, the company had cash and cash equivalents of $181 million.

    What’s New?

    During the past nine months, the company simplified assets, decreased and reorganized the organization, and drastically strengthened the balance sheet so that they could focus solely on the pivotal Phase 3 IMPALA 2 clinical trial. Furthermore, the trial is progressing as planned, and the timelines are still on schedule, with the first patient dosed just over a month ago, numerous sites now operational, and patients dosed. Importantly, the organization is continuing to incorporate key lessons acquired from the first IMPALA study in order to complete IMPALA 2 as efficiently and as thoroughly as feasible.

  • Savara Inc. (SVRA) stock gains in Pre-Market: Things you need to know

    Savara Inc. (SVRA) stock gains in Pre-Market: Things you need to know

    Shares of Savara Inc. (SVRA) continued to gain in Wednesday’s pre-market trading session. SVRA stock price saw an uptrend of 7.46% to reach $2.09 a share as of this writing. Savara stock was up by 21.56% at the previous closing. It seems that analyst rating is driving the SVRA stock price to high. Let’s understand the bullish sentiment in depth.

    Analyst Review on SVRA stock.

    Savara Inc. (SVRA) is working as an orphan disease lung company mainly focused on autoimmune pulmonary alveolar proteinosis (aPAP), a disease in which excessive protein in the lungs causes difficulty in breathing.

    Savara was performing well in the previous trading session and continuing the trend so far. Some of the street members believe that the current share price of SVRA stock points to the effective entry point. A famous piper sandler analyst Yasmeen Rahimi has given the buy rating to SVRA stock and set a $7 target price which suggests that SVRA stock has the potential to soar over 309% in the coming year.

    Rahimi thinks that Molgradexhas the great potential to treat autoimmune pulmonary alveolar proteinosis (PAP) and would be proved to be game-changer therapeutic in the future. Hence there is a strong possibility that SVRA stock would outperform in the future. The analyst further depicted the validation of Molgradex by saying that it has already received the Orphan Drug Designation in the U.S for seven years and EU for ten years in addition to Fast Track Designation and Breakthrough Therapy Designation by FDA.

    Previous Event

    Savara stock announced the public offering of shares of its common stock on March 10, 2021, which SVRA closed on March 15, 2021. A total of  57,479,978 shares were included in that offering at $1.45 per share. The net proceeds resulted from this offering were intended to support the working capital of Savara’s operations in different sectors.

    Conclusion:

    Savara stock is rising as investors are responding in response to the analyst rating. The three recent reviews of Buy with an average target price of $4.67 point to the 173% growth for this penny stock in the next year. Hence SVRA stock can be a good bet in long run.

  • SAVARA Inc. (SVRA) stock is soaring high by 12.68%. Let’s find out why?

    SAVARA Inc. (NASDAQ: SVRA) stock jumped high in the last trading, close by 15.82%, whereas the SVRA stock rises by 12.68% during the pre-market after announcing the closing of a $130 million public offering. SVRA is a pharmaceutical orphan lung disease company that deals with the development of efficient therapies to treat severe or life-threatening rare respiratory diseases. Currently, molgramostim is its lead program in its phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). SAVARA has its expertise in orphan drug development and pulmonary medicine to fulfill the unmet requirements.

    What is happening?

    SAVARA Inc. has today announced the completion of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold after the underwriters exercised their option to buy additional shares, at a public offering price of $1.45 per share.

    The net capital generated from this offering will be used to support SAVARA’s operations, including clinical research, production, regulatory, and commercial activities related to its molgramostim nebulizer solution (molgramostim, formerly known as Molgradex) in autoimmune pulmonary alveolar proteinosis (aPAP) program. The capital will also be used to support the IMPALA 2 trial and fulfill the general and administrative expenses.

    Other Recent Developments

    • Another positive development follows the rise in SVRA stock price: Piper Sandler initiated coverage on the stock with an overweight rating and a price target of $7 per share.
    • Also, the insiders are continuously buying the SVRA stock; the most recent insider purchase was by Director Ramsay, who has bought 689,655 shares in SVRA for $1,000,000. This has doubled his share count to 811,797 shares